Martha Gulati, MD, MS, FACC, FAHA

Articles by Martha Gulati, MD, MS, FACC, FAHA

Hypercortisolism Recognition and Action in Resistant Hypertension

ByDeepak Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI,Stephen Greene, MD,Martha Gulati, MD, MS, FACC, FAHA,Erin Michos, MD,Matthew J. Budoff, MD

July 7th 2026

In the final episode, ‘Hypercortisolism Recognition and Action in Resistant Hypertension,’ the panelists explored key takeaways from their discussion on the evolving role of hypercortisolism in resistant hypertension and cardiometabolic disease.

The Future of Hypercortisolism Care in Cardiology

ByDeepak Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI,Stephen Greene, MD,Martha Gulati, MD, MS, FACC, FAHA,Erin Michos, MD,Matthew J. Budoff, MD

July 7th 2026

In this episode, ‘The Future of Hypercortisolism Care in Cardiology,’ the panelists explore how increasing awareness of hypercortisolism may reshape cardiovascular practice, education, and multidisciplinary care models.

Emerging Therapies for Hypercortisolism

ByDeepak Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI,Stephen Greene, MD,Martha Gulati, MD, MS, FACC, FAHA,Erin Michos, MD,Matthew J. Budoff, MD

July 7th 2026

This episode, titled ‘Emerging Therapies for Hypercortisolism,’ features panelists discussing the evolving treatment landscape for hypercortisolism and the growing body of research aimed at improving outcomes for patients with resistant hypertension, diabetes, and other cardiometabolic complications.

Management and Treatment Goals in Hypercortisolism

ByDeepak Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI,Stephen Greene, MD,Martha Gulati, MD, MS, FACC, FAHA,Erin Michos, MD,Matthew J. Budoff, MD

July 7th 2026

In ‘Management and Treatment Goals in Hypercortisolism,’ our panel explores practical approaches to managing patients with hypercortisolism-associated hypertension following diagnosis and discusses the importance of addressing the underlying cause of disease.

Hypercortisolism Insights from MOMENTUM and CATALYST Trials

ByDeepak Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI,Stephen Greene, MD,Martha Gulati, MD, MS, FACC, FAHA,Erin Michos, MD,Matthew J. Budoff, MD

July 7th 2026

In this episode, ‘Hypercortisolism Insights from MOMENTUM and CATALYST Trials,’ the panelists explore the design, findings, and clinical implications of the MOMENTUM and CATALYST studies and discuss how emerging evidence is reshaping the understanding of hypercortisolism in resistant hypertension and difficult-to-control type 2 diabetes.

Guidelines and Barriers to Hypercortisolism Screening in Cardiology

ByDeepak Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI,Stephen Greene, MD,Martha Gulati, MD, MS, FACC, FAHA,Erin Michos, MD,Matthew J. Budoff, MD

July 7th 2026

This episode, titled ‘Guidelines and Barriers to Hypercortisolism Screening in Cardiology,’ features panelists discussing how recent clinical evidence and updated expert recommendations may influence the recognition and screening of hypercortisolism in patients with resistant hypertension and cardiovascular disease.

Hypercortisolism Screening in Cardiology Practice

ByDeepak Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI,Stephen Greene, MD,Martha Gulati, MD, MS, FACC, FAHA,Erin Michos, MD,Matthew J. Budoff, MD

July 7th 2026

In ‘Hypercortisolism Screening in Cardiology Practice,’ our panel explores the evolving role of cardiologists in identifying patients at risk for hypercortisolism and initiating appropriate screening evaluations.

Hypercortisolism and Other Secondary Causes of Hypertension

ByDeepak Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI,Stephen Greene, MD,Martha Gulati, MD, MS, FACC, FAHA,Erin Michos, MD,Matthew J. Budoff, MD

July 7th 2026

In this episode, ‘Hypercortisolism and Other Secondary Causes of Hypertension,’ the panelists explore how cardiologists should think about hypercortisolism in the context of other secondary causes of hypertension, particularly primary aldosteronism.

Recognizing Hypercortisolism in Cardiovascular Practice

ByDeepak Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI,Stephen Greene, MD,Martha Gulati, MD, MS, FACC, FAHA,Erin Michos, MD,Matthew J. Budoff, MD

July 7th 2026

This episode, titled ‘Recognizing Hypercortisolism in Cardiovascular Practice,’ features panelists discussing the patient presentations that should raise suspicion for underlying hypercortisolism in patients with hypertension and cardiovascular disease.

Prevalence of Hypercortisolism in Resistant Hypertension

ByDeepak Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI,Stephen Greene, MD,Martha Gulati, MD, MS, FACC, FAHA,Erin Michos, MD,Matthew J. Budoff, MD

July 7th 2026

In ‘Prevalence of Hypercortisolism in Resistant Hypertension,’ our panel explores the growing recognition of hypercortisolism as an important contributor to resistant hypertension, cardiovascular disease, and cardiometabolic dysfunction.

Hypercortisolism as a Driver of Hypertension and Cardiovascular Risk

ByDeepak Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI,Stephen Greene, MD,Martha Gulati, MD, MS, FACC, FAHA,Erin Michos, MD,Matthew J. Budoff, MD

June 30th 2026

In, ‘Hypercortisolism as a Driver of Hypertension and Cardiovascular Risk’, panelists will continue their discussion on hypercortisolism and highlight how cortisol excess can contribute to hypertension and cardiovascular risk even in the absence of classic Cushing syndrome features. They also explore emerging evidence linking hypercortisolism to adverse cardiometabolic outcomes and the implications for cardiovascular practice.

The Challenge of Resistant Hypertension

ByDeepak Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI,Stephen Greene, MD,Martha Gulati, MD, MS, FACC, FAHA,Erin Michos, MD,Matthew J. Budoff, MD

June 30th 2026

In this episode, ‘The Challenge of Resistant Hypertension,’ features the panelists discussing persistent barriers to blood pressure control, evolving hypertension management strategies, and the importance of recognizing secondary causes of resistant hypertension. They also explore how missed opportunities for diagnosis may contribute to ongoing cardiovascular risk in clinical practice.